Navigation Links
Pharmacyclics to Present at the RBC Capital Markets Healthcare Investor Conference
Date:2/26/2010

SUNNYVALE, Calif., Feb. 26 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of immune mediated diseases and cancer, announced that the Company will be participating at the RBC Capital Markets Healthcare Investor Conference in New York at the Palace Hotel on Tuesday, March 2nd. Dr. Joseph Buggy, Vice President of Research, will be on a panel titled, "New Targets in Cancer Therapy" starting at 8:00 A.M. Eastern Time and moderated by RBC analyst Jason Kantor.  

There will be a live webcast of the panel, which will be accessible through a link posted on the investor relations / events & webcasts section of the PCYC website, please go to http://ir.pharmacyclics.com/events.cfm

About Pharmacyclics

Pharmacyclics® is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of immune mediated disease and cancer. The purpose of the company is to create a profitable business by generating income from products it develops, licenses and commercializes, either with one or several potential partners or alone as may best forward the economic interest of its stakeholders. The Company endeavors to create novel, patentable, differentiated products that have the potential to significantly improve the standard of care in the markets it serves. Presently, Pharmacyclics has four product candidates in clinical development and two product candidates in pre-clinical development. It is Pharmacyclics' business strategy to establish collaborations with large pharmaceutical and biotechnology companies for the purpose of generating present and future income in exchange for adding to their product pipelines. Pharmacyclics strives to generate collaborations that allow it to retain valuable territorial rights and simultaneously fast forward the clinical development and commercialization of its products. The Company is headquartered in Sunnyvale, California and is listed on NASDAQ under the symbol PCYC. To learn more about how Pharmacyclics advances science to improve human healthcare visit us at http://www.pharmacyclics.com.

SOURCE Pharmacyclics, Inc.

Back to top

RELATED LINKS
http://www.pharmacyclics.com

'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmacyclics Reports Second Quarter Fiscal 2010 Financial Results
2. Pharmacyclics to Host Webcast and Conference Call to Discuss Clinical Updates on Its HDAC and BTK Program as Presented at The American Society of Hematology Meeting Dec. 6 & 7
3. Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology
4. Pharmacyclics to Present at Merriman Curhan Fords Investor Summit 2009
5. Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier
6. Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkins Lymphoma
7. Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.
8. Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
9. Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma
10. Pharmacyclics Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer
11. Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... , April 29, 2016 ... for Life Sciences, Product Development Capabilities in ... Science Customer Base . Indegene ... today announced the acquisition of Skura Corporation,s life ... leader in adaptive sales enablement technology for life ...
(Date:4/28/2016)... April 28, 2016   Click here for ... Inc. (NYSE: DPLO), the nation,s largest independent specialty ... definitive agreement to acquire Valley Campus Pharmacy, Inc., ... a leading specialty pharmacy that provides individualized patient ... . In 2015, TNH generated approximately $400 ...
(Date:4/28/2016)... April 28, 2016 ... George Phillips und Stephen Schmidt ... ArisGlobal®, ein führender Anbieter cloudbasierter ... heute bekannt, dass neue Führungskräfte zum Team ... sind, die vielfältige Erfahrungen mitbringen.  Dies wird ...
Breaking Medicine Technology:
(Date:5/3/2016)... ... , ... Park Cities Pet Sitter has openings for both full-time and part-time ... 75209, 75219, 75220, 75225, 75229, 75230, 75231 and 75235 zip codes. These zip ... Hollow and Park Cities areas of the Metroplex. Candidates must love animals, have ...
(Date:5/3/2016)... Toronto, ON (PRWEB) , ... May 03, 2016 ... ... been recognized as one of Canada’s top Information and Communication Technology (ICT) companies ... top Canadian and Multinational ICT companies operating in Canada, as ranked by revenue. ...
(Date:5/3/2016)... (PRWEB) , ... May 03, 2016 , ... ... general availability of the latest release of DocAve 6 Service Pack (SP) ... helps organizations migrate to SharePoint 2016 and take advantage of the platform’s latest ...
(Date:5/3/2016)... ... May 03, 2016 , ... Hydra Skin Sciences, a top-rated skincare company ... a revolutionary new anti-aging skin care product that integrates Snow Algae Powder ... sold over seventy-five thousand units worldwide within the first two months of release. , ...
(Date:5/3/2016)... ... May 03, 2016 , ... ... the state-of-the-art Carnival Vista – the line’s largest cruise ship ever. To ... has created an infographic spotlighting the Carnival Vista ’s most exciting ...
Breaking Medicine News(10 mins):